A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Imarikiren (Primary) ; Candesartan cilexetil
- Indications Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 10 Jan 2015 New trial record